D-Wave Takes Giant Leap in Computing with Advantage

Everyone in computing is familiar with the idea of Moore's Law, that computing power doubles every two years, but quantum computing could be making that premise a bit of an anachronism. Recently growth in the field of quantum computing has been accelerating at a rate that makes this seem like an antiquated adage of a simpler time.

This is especially evident in the news this week that D-Wave systems have released the first quantum computer designed to be used in commercial applications, The Advantage. The Advantage features 5000 connected qubits, a number that Frederic Lardinois from TechCrunch notes is over 2.5 times as large as their previous offering of 2000 connected qubits. This larger hardware is able to interconnect 15 interconnections simultaneously versus utilizing 6 interconnections in previous iterations.

These changes create a massive explosion in the computing power offered by the Advantage computer, giving it the ability to handle up to 1 million independent variables. Using their advanced Pegasus chip to link qubits, the computer is able to natively solve problems with between 600-800 variables, providing for a wide variety of commercial applications. As D-Wave CEO Alan Baratz told Emil Protalinski of Venture Beat, "There is no other quantum computer anywhere in the world that can solve problems at the scale and complexity that this quantum computer can solve problems. It really is the only one that you can run real business applications on. The other quantum computers are primarily prototypes. You can do experimentation, run small proofs of concept, but none of them can support applications at the scale that we can.

Putting computing power like this in the hands of innovators, researchers, and companies that are seeking to solve previously unsolvable problems is tremendously empowering. POLARISqb will have the ability to utilize platforms like the Advantage to power chemical and molecular searches on a scale that was previously unfathomable in the industry, optimizing the pace of drug discovery in ways never seen in the biotech and pharmaceutical industries. With the pace of innovation in the world of quantum expected to continue and accelerate, it is our goal to make molecular analysis and protein targeting faster than ever before, developing the ability to provide treatments and cures for all diseases and all people.